PHARMACEUTICAL COMPOSITION COMPRISING A LTB4 ANTAGONISTS AND A COX-2 INHIBITOR OR A COMBINED COX 1/2 INHIBITOR

Izum se odnosi na farmaceutsku formulaciju koja sadrži LTB4 antagonist s hidroksi i benzamidinskom skupinom, ili njegov tautomer, farmaceutski prihvatljivu sol, solvat ili njegov fiziološki funkcionalan derivat, posebno spoj formule (I)u kojoj su R i A definirani kao u patentnim zahtjevima, ili njegov tautomer, farmaceutski prihvatljivu sol, solvat ili njegov fiziološki funkcionalan derivat (1), i najmanje jedan inhibitor ciklooksigenaze 2, kombinirani cox1/2 inhibitor ili njegovu farmaceutski prihvatljivi sol, solvat ili njegov fiziološki funkcionalan derivat (2), i farmaceutski prihvatljiv nosač ili pomoćno sredstvo, i prema potrebi jedan ili više drugih terapeutskih sastojaka. The invention relates to a pharmaceutical formulation comprising a LTB4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, in particular a compound of formula (I) wherein R and A are as defined in the claims, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (1) and at least one cyclooxygenase-2 inhibitor, a combined cox1/2 inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (2), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.